menu search

IKNA / Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? Read More
Posted: Mar 14 2023, 09:58
Author Name: Zacks Investment Research
Views: 102628

IKNA News  

Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why

By Zacks Investment Research
June 20, 2023

Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why

Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the more_horizontal

Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why

By Zacks Investment Research
June 2, 2023

Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why

Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the more_horizontal

Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?

By Zacks Investment Research
May 5, 2023

Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?

Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisi more_horizontal

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 14, 2023

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the n more_horizontal

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

By GlobeNewsWire
March 7, 2022

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-direct more_horizontal


Search within

Pages Search Results: